(Press-News.org) Houston, TX (November 8, 2025) — A 5-year study revealed a stability of globalacute kidney injury (AKI)–related mortality rates with differing patterns that indicate a rising concentration of mortality in older populations and higher socioeconomiccountries. The findings will be presented at ASN Kidney Week 2025 November 5– 9.
When investigators at the Kyung Hee University Hospital in Seoul assessed AKI-related mortality trends in 43 countries from 1996–2021 using the WHO MortalityDatabase, they found that high-income countries showed an upward trend, whilelow- and middle-income countries experienced a decline. Older adults, especially females, in high socioeconomic settings demonstrated increasing mortality trends, and future projections indicated a gradual rise in global AKI-related mortality through 2050.
More detailed analyses revealed that although high-income countries have lowerAKI- related mortality rates, they have experienced gradual increases largelyattributable to population aging and higher comorbidity burden, while in low- and middle-income countries, declining mortality has been associated with younger populations and improvements in infection control and health care access.
“Our study provides the first global long-term analysis and projections of AKI-related mortality, offering critical insights for policymakers and health systems,” said lead author Hyeon Seok Hwang, MD, PhD. “These findings underscore theneed for tailored, region-, age-, and sex-specific strategies to mitigate the future burden of AKI,” added co-author Soo-Young Yoon, MD, PhD. “Additional studies are needed to continue monitoring AKI- related mortality and the effectiveness of different strategies to prevent it, said co-author Jeong-Yeun Lee, MD.
Study: “Temporal Trends in AKI-Related Mortality Across 43 Countries, 1996-2021,with Projections up to 2050: A Global Time Series Analysis and Modelling Study”
Join ASN and approximately 12,000 other kidney professionals from across the globe at Kidney Week 2025 in Houston, TX. The world's premier nephrology meeting, Kidney Week, provides participants with exciting and challenging opportunities to exchange knowledge, learn the latest scientific and medical advances, and listen to engaging andprovocative discussions with leading experts in the field. Early programs begin on November 5, followed by the Annual Meeting from November 6-9. Follow the conversation at #KidneyWk.
About the American Society of Nephrology (ASN)
Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseasesthroughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge and advocating for the highest quality care for patients. ASN has nearly 22,000 members representing 141 countries. For more information, visit www.asn- online.org and follow us on Facebook, X, LinkedIn, and Instagram.
# # #
END
Houston, TX (November 8, 2025) — The current kidney transplant waitlistingcriterion is based on a single measurement of kidney function (estimated glomerular filtration rate [eGFR] ≤20 ml/min/1.73m2) and does not consider an individual’s risk of progressing to kidney failure. A new study reveals that inclusion of a patient’s 2-year risk of progression to kidney failure (using theKidney Failure Risk Equation [KFRE], which incorporates age, ...
Houston, TX (November 8, 2025) — The cost of emergency dialysis is estimated to be 8-times that of in-center dialysis. A new study reveals that a transitional dialysis program piloted in Travis County (Austin, TX) resulted in a significant decrease in emergency department visits and hospital admissions for emergency dialysis by providing a pathway for outpatient dialysis in uninsured patients. Thefindings will be presented at ASN Kidney Week 2025 November 5– ...
Houston, TX (November 8, 2025) — Metformin-associated lactic acidosis(MALA) is a rare but serious adverse effect of the diabetes drug metformin in which the body accumulates too much lactic acid. Investigators developed and tested a protocol for diagnosis and treatment of MALA. Their work will be presented at ASN Kidney Week 2025 November 5– 9.
The protocol, which included immediate initiation of dialysis using either intermittent hemodialysis, continuous kidney replacement therapy, or peritonealdialysis as treatment, ...
Houston, TX (November 8, 2025) — It can be challenging to identify which patients with advanced chronic kidney disease (CKD) will most benefit from conservative care rather than initiating dialysis. Researchers recently developed and validated a prediction model to estimate individualized survival probabilities with conservative non-dialytic management versus dialysis in patients with advanced CKD from the national Veterans Affairs and OptumLabs® DataWarehouse databases. The work will be presented at ASN Kidney Week 2025 November 5–9.
Investigators found that among veterans with advanced CKD who received dialyticversus ...
In a new study of more than 40,000 patients, researchers at Intermountain Health in Salt Lake City have found that patients who have no evidence of calcium in their coronary arteries are not only significantly less likely to die from heart conditions – including heart attacks and heart failure– but also are at reduced risk of death from non-cardiac medical conditions.
Coronary artery calcium (CAC) is a strong predictor of how likely someone is to develop clinical coronary artery disease. It is an excellent measure of coronary plaque burden.
When cholesterol-laden plaque builds up in the coronary arteries, blood flow to heart muscle is limited, and plaque rupture with coronary ...
Coronary artery calcium (CAC) CT scans are becoming a more commonly used tool to effectively determine a patient’s future risk of heart disease and heart attack.
These minimally invasive scans measure how much calcium is already present in the arteries of the heart, so that clinicians can determine if a patient needs medical intervention or other preventative measures, including statin medications.
Now an important new study from heart researchers at Intermountain Health in Salt Lake City ...
Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce albuminuria (excess albumin in the urine) and the risk of chronic kidney disease (CKD) progression, and certain mineralocorticoid receptor antagonists have similar effects in people with type 2 diabetes and CKD. Investigators recently assessed the albuminuria-lowering efficacy and safety of the novel mineralocorticoid receptor antagonist balcinrenone combined with the SGLT2 dapagliflozin. In the double-blind, active-controlled clinical trial, both doses of this novel balcinrenone/dapagliflozin combination outperformed dapagliflozin alone, cutting levels of ...
Researchers from Mass General Brigham have unveiled the results of a large clinical trial that found that adding the drug evolocumab to patients’ treatment significantly reduced the risk of major adverse cardiovascular events in those who are at high risk. Results were presented today at the American Heart Association Scientific Sessions and simultaneously published in The New England Journal of Medicine.
“The results of this trial offer hope for preventing a first heart attack, stroke, or other ...
Researchers from Mass General Brigham have found that olezarsen—a drug designed to lower triglyceride levels—can also decrease the risk of acute pancreatitis, a potential complication in patients with severely elevated triglyceride levels. The results, from two randomized, placebo-controlled trials (CORE-TIMI 72a and CORE2-TIMI 72b), were presented at the American Heart Association Scientific Sessions and simultaneously published in The New England Journal of Medicine.
Severe hypertriglyceridemia is a condition in which the level of triglycerides (a type of fat that circulates in the blood) is very high. Approximately 1 in 100 people in the U.S. have severe hypertriglyceridemia. ...
Steatotic liver disease (SLD), mainly encompassing metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease (ALD), and metabolic dysfunction and ALD (MetALD), has emerged as the dominant cause of chronic liver disease worldwide, displacing viral hepatitis as the primary aetiology. Globally, the prevalence of MASLD is estimated even over 30%, affecting over one-third of adults. Parallelly, alcohol remains a major risk factor, with heavy drinking contributing to 90–95% of SLD cases and up to 10% advancing to cancer.
Genetic ...
